Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) has been assigned an average recommendation of “Hold” from the seven analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $6.2333.
A number of research firms have commented on IRWD. Citizens Jmp raised their price objective on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Sunday, May 17th. Jefferies Financial Group restated a “hold” rating and set a $3.70 price objective on shares of Ironwood Pharmaceuticals in a research note on Thursday, February 26th. Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, April 27th.
Check Out Our Latest Research Report on IRWD
Insider Activity
Hedge Funds Weigh In On Ironwood Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the business. LSV Asset Management bought a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $30,000. Jump Financial LLC bought a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $34,000. DGS Capital Management LLC bought a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $35,000. Cibc World Markets Corp bought a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $36,000. Finally, Simplify Asset Management Inc. bought a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $37,000.
Ironwood Pharmaceuticals Price Performance
Ironwood Pharmaceuticals stock opened at $3.65 on Wednesday. The stock’s fifty day moving average price is $3.82 and its two-hundred day moving average price is $3.88. Ironwood Pharmaceuticals has a one year low of $0.61 and a one year high of $5.78. The firm has a market cap of $595.17 million, a PE ratio of 6.08 and a beta of 0.25.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%.The company had revenue of $106.51 million for the quarter, compared to the consensus estimate of $92.11 million. Sell-side analysts expect that Ironwood Pharmaceuticals will post 1.04 earnings per share for the current fiscal year.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.
Featured Stories
- Five stocks we like better than Ironwood Pharmaceuticals
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
